IL-17 is an important player in the establishment of prostatic inflammation, and can be considered a modulator of BPH immune responses, by maintaining the local inflammatory microenvironment and amplifying the damage to prostatic tissue8. Here, IL17A is linked to benign prostatic hyperplasia.